Browsing Tag
Trelegy Ellipta
2 posts
GSK wins China approval for Trelegy Ellipta in asthma, expanding respiratory market reach
Trelegy Ellipta is now approved for asthma in China, giving GSK dual coverage in COPD and asthma. Find out what this means for respiratory market dynamics.
Theravance Biopharma cashes out remaining Trelegy royalties in $225m deal with GSK
Theravance Biopharma sells Trelegy royalties to GSK for $225M, unlocking shareholder value and reinforcing its focus on YUPELRI and ampreloxetine.